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I M M U N O L O G Y
Control of intestinal inflammation by 
glycosylation-dependent lectin-driven 
immunoregulatory circuits
Luciano G. Morosi1,2†, Anabela M. Cutine1,2, Alejandro J. Cagnoni1,2, Montana N. Manselle-Cocco2, 
Diego O. Croci3, Joaquín P. Merlo1,4, Rosa M. Morales2, María May5, Juan M. Pérez-Sáez2,  
María R. Girotti4, Santiago P. Méndez-Huergo2, Betiana Pucci6, Aníbal H. Gil6,  
Sergio P. Huernos6, Guillermo H. Docena7, Alicia M. Sambuelli6, Marta A. Toscano2,  
Gabriel A. Rabinovich2,4,8*‡, Karina V. Mariño1*‡
Diverse immunoregulatory circuits operate to preserve intestinal homeostasis and prevent inflammation. Galectin-1 
(Gal1), a -galactoside–binding protein, promotes homeostasis by reprogramming innate and adaptive immunity. 
Here, we identify a glycosylation-dependent “on-off” circuit driven by Gal1 and its glycosylated ligands that con-
trols intestinal immunopathology by targeting activated CD8+ T cells and shaping the cytokine profile. In patients 
with inflammatory bowel disease (IBD), augmented Gal1 was associated with dysregulated expression of core 2 
6-N-acetylglucosaminyltransferase 1 (C2GNT1) and (2,6)-sialyltransferase 1 (ST6GAL1), glycosyltransferases re-
sponsible for creating or masking Gal1 ligands. Mice lacking Gal1 exhibited exacerbated colitis and augmented 
mucosal CD8+ T cell activation in response to 2,4,6-trinitrobenzenesulfonic acid; this phenotype was partially 
ameliorated by treatment with recombinant Gal1. While C2gnt1−/− mice exhibited aggravated colitis, St6gal1−/− 
mice showed attenuated inflammation. These effects were associated with intrinsic T cell glycosylation. Thus, 
Gal1 and its glycosylated ligands act to preserve intestinal homeostasis by recalibrating T cell immunity.
INTRODUCTION
Inflammatory bowel diseases (IBDs) encompass a large range of 
chronic pathologies. Crohn’s disease (CD) and ulcerative colitis 
(UC) are unique disorders characterized by inflammation of the 
gastrointestinal tract that result in increased risk of colorectal can-
cer and a marked decrease in life quality of affected individuals (1). 
Over the past decade, IBD has become a global burden. While the 
incidence of these disorders has stabilized in Western countries, it 
has increased considerably in newly industrialized regions of Africa, 
Asia, and South America (2). While administration of monoclonal 
antibodies that target proinflammatory mediators [i.e., anti–tumor 
necrosis factor (TNF)] and gut-homing molecules (i.e., 47 integrin) 
have reshaped the landscape of IBD treatment (3), the serious ad-
verse effects observed in certain patient cohorts together with the 
high percentage of primary or secondary resistance highlight the 
need for alternative therapeutic approaches (4, 5).
Galectins, a family of soluble glycan-binding proteins, can modu-
late immune cell homeostasis and reprogram innate and adaptive im-
mune responses, acting as danger-associated or resolution-associated 
molecular patterns (6–10). Altered expression of these lectins has 
been observed within the gastrointestinal tract in several pathologic 
conditions including IBD (11, 12). Most extracellular activities of 
galectins are regulated by the availability of specific N- and O-glycan 
structures on the surface of immune cells (13). Programmed re-
modeling of these glycosylated ligands, through the coordinated 
action of glycosyltransferases and glycosidases, is tightly controlled 
by environmental cues, including those arising from cytokines, 
hypoxia, and inflammation (8).
Intestinal inflammation can result in structural changes that 
ultimately alter the extent and nature of protein glycosylation, both 
locally and systemically, as a component of the natural history of 
the disease (14). Circulating aberrantly glycosylated immunoglobu-
lin G (IgG) has been identified as a potential disease biomarker in 
inflammatory diseases, including IBD (14, 15). Likewise, altered 
glycosylation of mucins has a profound influence on the develop-
ment of intestinal inflammation (16, 17). Moreover, mice devoid of 
glycosyltransferases implicated in O-glycan biosynthesis, such as 
core 2 6-N-acetylglucosaminyltransferase 1 (C2GnT1), its isoform 
C2GnT3, or 1,3-galactosyltransferase C1GalT1, all exhibited in-
creased susceptibility to intestinal inflammation in response to ad-
ministration of dextran sulfate sodium (DSS) (18, 19). Genome-wide 
association studies identified COSMC, a gene in the X chromosome 
that encodes a key chaperone involved in core 1/core 2 O-glycan 
biosynthesis, as an IBD risk factor. Deletion of this gene from mouse 
intestinal epithelial cells leads to the development of dysbiosis similar 
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to that observed in patients with IBD (20). An altered CD4+ memory 
T cell O-glycome has been shown to contribute to exacerbation of 
colitis due to interactions with epithelial-derived galectin-4 (Gal4) (21). 
Moreover, activity of (1,6)N-acetylglucosaminyltransferase 5 (Mgat5), 
an enzyme responsible for generating complex branched N-glycans 
in mucosal T cells, has been shown to influence disease severity in 
patients diagnosed with UC (22). However, and despite considerable 
progress, the clinical and immunological significance of galectins 
proteins in the pathogenesis of IBD and their association with ab-
errant glycosylation remain poorly understood.
Gal1, a prototype member of the galectin family, controls several 
immune cell processes including activation, differentiation, trafficking, 
and survival through specific recognition of N-acetyllactosamine 
[LacNAc; Gal(1-4)GlcNAc]–containing structures on cell surface 
glycosylated receptors (Fig. 1) (9). Among these activities, the ac-
tions of Gal1 serve to limit the survival of T helper cell 1 (TH1)– and 
TH17-differentiated cells (23), to fine-tune the immunogenicity of 
dendritic cells (DCs) (24), and to promote contraction of the CD8+ 
T cell compartment (25), leading to induction of tumor-immune 
escape (26, 27), modulation of microbial infections (28), and resolu-
tion of autoimmune inflammation (8). Several intrinsic factors govern 
the biological activity of Gal1, including its monomer-dimer equi-
librium and redox status, as well as the availability of specific glycan- 
binding sites on different cellular receptors (29). Hence, the altered 
expression of glycosyltransferases is responsible for creating or mask-
ing glycan epitopes that can interact with Gal1 and thus can influ-
ence its biological activity. Of particular note, (2,6)-sialyltransferase 1 
(ST6Gal1) catalyzes the incorporation of (2,6)-linked sialic acid to 
terminal galactose residues, thereby hindering their recognition by 
Gal1. In turn, Mgat5 and C2GnT1 activities contribute to the cre-
ation of a permissive glycosylation signature that favors Gal1 binding 
and function (Fig. 1) (6, 30). Administration of exogenous recombi-
nant Gal1 (rGal1) promoted resolution of 2,4,6-trinitrobenzenesulfonic 
acid (TNBS)–induced colitis in BALB/c mice via suppression of 
proinflammatory cytokine production in the gut mucosa (31). 
However, the roles of endogenous Gal1 and its glycosylated ligands 
in modulating mucosal immunity and intestinal immunopathology 
remain unexplored. In this study, we used experimental models of coli-
tis and clinical specimens from patients with IBD to perform an inte-
grated analysis of the Gal1-glycan axis, specifically its role in altering 
the nature of the mucosal immune landscape and its contributions to 
the development, severity, and resolution of intestinal inflammation.
RESULTS
Inflammation alters the expression of galectins and specific 
glycosyltransferases in colon biopsies from patients with IBD
We first analyzed the expression of galectin genes in colon biopsies 
from patients with IBD based on inflammation severity of human 
intestinal mucosa, binarized into either inflamed or uninflamed 
categories as well as in healthy individuals using publicly available 
datasets. In line with previous reports (32), no significant differences 
were observed in the expression of galectins and glycosyltransferases 
when comparing inflamed or uninflamed colonic tissue in patients 
with CD and patients with UC (fig. S1). Considering these results, 
and the similar dysregulation of galectins previously described in 
biopsies from CD and UC in inflamed areas (12), we analyzed data 
based on disease activity (inflamed or uninflamed as defined at the 
time of the colonoscopy). Whereas expression of Gal1 (encoded by 
LGALS1) was up-regulated in inflamed compared to uninflamed 
areas of the colon, and those from healthy controls, expression of 
Gal8 (LGALS8) and Gal9 (LGALS9) was not altered and Gal2 
(LGALS2), Gal3 (LGALS3), and Gal4 (LGALS4) were found to be 
down-regulated (Fig. 2A). Given their immunoregulatory potential 
(12), we then analyzed the expression of LGALS1, LGALS3, LGALS4, 
and LGALS9 mRNA by reverse transcription quantitative poly-
merase chain reaction (RT-qPCR) in a local cohort of patients 
(Table 1). Notably, Gal1 was the only member of the galectin family con-
sistently and significantly up-regulated in biopsies from inflamed 
areas of the colon (Fig. 2, A and B). However, plasma concentrations 
of Gal1 were not significantly different in our local cohort of patients 
with IBD when compared to controls (fig. S2, A and B).
We then analyzed the expression of three glycosyltransferases that 






































































Fig. 1. Schematic representation of N- and O-glycan biosynthetic pathways. Complex N-glycans are synthesized in several steps, including trimming by -mannosidases 
and the sequential actions of N-acetylglucosaminyltransferases (MGATs). MGAT5 is the enzyme responsible for (1,6) branching. The GlcNAc residues can be extended 
to LacNAc structures via the actions of galactosyltransferases (GALTs); the terminal galactose residues will ultimately undergo (2,6) sialylation by ST6GAL1. While 
(1,6) branching favors Gal1 binding, (2,6) sialylation inhibits Gal1 recognition of terminal LacNAc structures. Biosynthesis of O-glycans is initiated by polypeptide 
N-acetylgalactosamine transferases (ppGALNAcTs). Biosynthesis of core 1 is achieved by the action of (1,3) galactosyltransferase C1GALT1 with assistance from core 1 
(1,3) galactosyltransferase–specific molecular chaperone (COSMC). The resulting disaccharide can undergo branching via the actions of (1,6) GlcNAc transferases, 
including C2GNT1 (also called GCNT1), resulting in the generation of core 2 O-glycans. Last, core 2 O-glycans can be further decorated by GALTs, resulting in the synthesis 
of LacNAc that is recognized by Gal1. Glycans are depicted following the guidelines from the Symbol Nomenclature for Glycans group (72).
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HC-U: P = 0.9953; HC-I: P < 0.0001; U-I: P < 0.0001
HC-U: P = 0.2198; HC-I: P < 0.0001; U-I: P = 0.0006
HC-U: P = 0.5489; HC-I: P < 0.0001; U-I: P < 0.0001
HC-U: P = 0.7714; HC-I: P < 0.0001; U-I: P < 0.0001
HC-U: P = 0.0247; HC-I: P = 0.5587; U-I: P = 0.1223
HC-U: P = 0.9883; HC-I: P = 0.8000; U-I: P = 0.6317
HC-U: P = 0.0159; HC-I: P = 0.9680; U-I: P = 0.0074
HC-U: P = 0.6750; HC-I: P = 0.0078; U-I: P < 0.0001
HC-U: P = 0.8349; HC-I: P = 0.0234; U-I: P = 0.0433












Fig. 2. Dysregulated expression of Gal1 and specific glycosyltransferases in IBD. (A) Bioinformatic analysis of galectin expression (LGALS1, LGALS2, LGALS3, LGALS4, LGALS7, 
LGALS8, and LGALS9) in IBD datasets. (B) Expression of LGALS1, LGALS3, LGALS4, and LGALS9 analyzed by RT-qPCR in colon biopsies from healthy controls (n = 8), unin-
flamed (n = 13), and inflamed (n = 11) areas from colon biopsies of a local cohort of patients with IBD. (C) Bioinformatic analysis of glycosyltransferases relevant for Gal1 binding 
(ST6GAL1, MGAT5, and C2GNT1) in IBD datasets. (D) Expression of ST6GAL1, MGAT5, and C2GNT1 analyzed by RT-qPCR in colon biopsies from healthy controls (n = 6), unin-
flamed (n = 15), and inflamed (n = 14) areas from colon biopsies of a local cohort of patients with IBD. In (A) and (C), two-way analysis of variance (ANOVA) followed by 
Tukey’s posttest was used; colors in the heatmap depict the logarithm (base 2) of the fold change (log2FC), comparing uninflamed (U) and inflamed (I) areas of colon 
biopsies from patients with IBD with healthy controls (HC). In (B) and (D), one-way ANOVA followed by Tukey’s posttest was used. Unless otherwise stated, data are presented 
as means ± SEM. HC-U, healthy controls vs. uninflamed areas; HC-I, healthy controls vs. inflamed areas; U-I, uninflamed vs. inflamed areas. *P < 0.05 and **P < 0.01.
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ligands. We found considerable up-regulation of ST6GAL1, an 
(2,6)-sialyltransferase capable of generating glycan structures that 
prevent Gal1 recognition and function (Fig. 1), in biopsies from in-
flamed areas of patients with IBD (Fig. 2C). C2GNT1, an enzyme 
that creates Gal1-specific ligands by generating core 2 O-glycans 
(Fig. 1), and MGAT5, a glycosyltransferase involved in complex 
N-glycan branching, were both down-regulated in inflamed areas 
of the colon (Figs.  1 and 2C). Dysregulation of ST6GAL1 and 
C2GNT1 was validated by RT-qPCR analysis in the same patient 
cohort used for analysis of galectins (Fig. 2D). Of note, there were 
no significant changes in MGAT5 expression when comparing colon 
biopsies of both inflamed and uninflamed areas from patients with 
IBD with those of healthy controls (Fig. 2D). Thus, down-regulation 
of C2GNT1 and up-regulation of ST6GAL1 in inflamed areas of 
patients with IBD suggest the likelihood of exhibiting an aberrant 
glycome; these alterations could serve to modulate the capacity for 
Gal1 binding and thereby influence its immunoregulatory activity.
Endogenous Gal1 controls TNBS-induced intestinal 
inflammation via its impact on the effector T cell compartment
The up-regulation of Gal1  in colon biopsies of patients with IBD 
prompted us to investigate the impact of endogenous Gal1 on the 
establishment and resolution of intestinal inflammation. For this, 
we compared the course of the disease in a double-dose TNBS- 
induced colitis model in both wild-type (WT) and Gal1-deficient 
(Lgals1−/−) C57BL/6 mice. We found that Lgals1−/− mice developed 
more severe colitis, with increased weight loss and a higher colonic 
weight/length ratio when compared to WT mice, although no 
Table 1. Clinical description of patients with IBD. Controls, healthy individuals; UC, ulcerative colitis; CD, Crohn’s disease. IQR, interquartile range; 5-ASA, 
5-aminosalicylic acid (mesalamine); 6-MP, 6-mercaptopurine; AZA, azathioprine; ATB, antibiotics; upper GIT, upper gastrointestinal tract; 0, nonexistent; -, not 
applicable. 
Patients with UC Patients with CD









N° of patients 9 7 7 6 5 1 11








11.5 (4–17) 2 (1–5) 1.5 (1–5) 10.5 (7–14) 4 (2–8) 1 -
Active smokers 1 1 1 1 0 0 3
Location UC
E1, proctitis 0 3 0 - - -
E2, left sided 5 0 4 - - -
E3, pancolitis 4 4 3 - - -
Location CD
L1, ileal - - - 0 0 0
L2, colon - - - 3 5 1
L3, ileocolonic - - - 3 0 0
L4, upper GIT - - - 0 0 0
Medication
5-ASA 5 3 0 0 0 0
Steroids 0 2 5 1 1 0
6-MP/AZA 2 0 0 0 0 0
5-ASA/steroids 0 2 2 1 0 0
5-ASA/AZA/6-MP 2 0 0 3 0 0
5-ASA/AZA/
steroids 0 0 0 0 2 0
5-ASA/ATB 0 0 0 0 1 0
AZA/ATB 0 0 0 0 1 0
Steroids/ATB 0 0 0 0 0 1
No medication 0 0 0 1 0 0
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Fig. 3. Lack of endogenous Gal1 exacerbates TNBS-induced colitis. (A) Weight loss curves of WT and Lgals1−/− mice treated with ethanol (vehicle) or TNBS. Data are 
from five independent experiments; two-way repeated-measures ANOVA followed by Tukey’s posttest. (B) Colon weight/length ratio. (C) Histopathologic assessment 
(score) of experimental groups. (D) Determination of Gal1 at day 10 in colon tissue by enzyme-linked immunosorbent assay (ELISA), normalized to total protein in WT 
mice. Box plots represent median (line), first and third quartiles (box limits), and minimum and maximum values (bars) from a representative of two independent experi-
ments (n = 6 mice per group); unpaired Student’s t test. (E) Detection of Gal1 at euthanize (day 10) in colon protein extracts from WT mice by Western blot. (F) Correlation 
between Gal1 protein levels and colon weight/length ratio (n = 11 mice); Pearson’s correlation coefficient (r) and P value (P) are indicated. (G and H) CD69 expression 
among CD4+ (G) or CD8+ (H) T cell populations within MLNs or cLP from vehicle- or TNBS-treated WT or Lgals1−/− mice. Data are from a representative of three indepen-
dent experiments (n = 10 mice per group). (I) Regulatory T cells (Tregs) in MLNs and cLP of vehicle-treated or TNBS-treated WT or Lgals1−/− mice. Data are from a representative 
of three independent experiments (n = 10 mice per group). (J) Expression of cytokines mRNA in colon from TNBS-treated WT or Lgals1−/− mice measured by RT-qPCR. Colors 
shown in the heatmap depict the log2FC for each cytokine in TNBS- versus vehicle-treated mice of each genotype. Multiple t test. In (B), (C), and (G) to (I), two-way ANOVA 
followed by Tukey’s posttest. Unless otherwise stated, data are presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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differences in histological grading were observed (Fig. 3, A to C). 
Similar to the findings from our analysis of patients with IBD, 
we detected significantly increased expression of Gal1 protein at 
day 10 in the colonic tissue of TNBS-treated WT mice when com-
pared to mice treated with vehicle alone (Fig. 3, D and E). Moreover, 
expression of Gal1 protein correlated positively with colon weight/
length ratio (Fig. 3F). Gal1 immunoreactivity was detected primarily 
within the interstitial spaces between cells of the lamina propria and 
was not restricted to a particular cell type (fig. S3).
To investigate possible mechanisms underlying the distinct re-
sponses of WT and Lgals1−/− mice in the TNBS-colitis model, and 
given our current understanding of the immunoregulatory role of 
this lectin with respect to activated peripheral CD4+ T cells (23, 31), 
our first experiments focused on T cells identified in the mesenteric 
lymph nodes (MLNs) and colonic lamina propria (cLP). A higher 
percentage of CD69-expressing CD4+ T cells was found in MLNs 
of TNBS-treated Lgals1−/− mice compared to both vehicle-treated 
Lgals1−/− and TNBS-treated WT mice (Fig. 3G). The induction of 
experimental colitis had no significant impact on the percentage of 
activated CD4+ T cells in the cLP in either genotype (Fig. 3G). 
Moreover, TNBS-treated Lgals1−/− mice exhibited a significant in-
crease in the percentage of CD69-expressing CD8+ T cells in both 
the MLNs and cLP compared to their WT counterpart (Fig. 3H). 
Given that CD69 is also a marker of T cell residency in cLP (33), we 
then examined CD69 and CD103 coexpression to elucidate whether 
increased CD8+CD69+ T cells observed in TNBS-treated Lgals1−/− 
mice were associated specifically with T cell activation or whether 
they represented a greater proportion of resident T cells (particularly 
tissue-resident memory T cells). We found no significant differences in 
these phenotypic markers regardless of the genotype or treatment (fig. 
S4); these results suggested that the increased frequency of CD8+CD69+ 
cells is most likely attributed to T cell activation. In addition, we 
ruled out the possibility that this finding could result from impaired 
expansion and/or recruitment of regulatory CD4+CD25+Foxp3+ 
T cells (Tregs), as TNBS-treated mice exhibited an increased propor-
tion of Tregs in MLNs regardless of their genotype, while no changes 
were observed in the cLP (Fig. 3I). We then compared the expres-
sion of effector T cell cytokines in the colon of TNBS- or vehicle- 
treated mice by RT-qPCR. We found higher levels of Il17a mRNA 
in WT mice but no significant changes in the expression of Il5, Il10, 
and Ifng mRNA when compared to vehicle-treated mice (Fig. 3J); 
by contrast, Lgals1−/− mice exhibited higher levels of Ifng and Il10 
with no changes in Il5 and Il17a mRNA expression (Fig. 3J). Last, 
Tnf mRNA expression was not significantly different between WT 
and Lgals1−/− TNBS-treated mice (fig. S5). Together, our findings 
suggest that endogenous Gal1 controls intestinal inflammation by 
reprogramming the fate of effector T cells and by altering the cyto-
kine balance in the gut microenvironment.
We then explored the possibility that administration of rGal1 
could promote resolution of exacerbated colitis in TNBS-treated 
Lgals1−/− mice. Of note, rGal1 reached the cLP when administered 
daily (100 g per mouse/day) to TNBS-treated Lgals1−/− mice (fig. 
S6). Daily administration of rGal1 in TNBS-treated Lgals1−/− mice 
resulted in decreased weight loss and reduced colonic weight/length 
ratio (Fig. 4, A and B). In addition, treatment with rGal1 resulted in 
partial restoration of mucosal integrity as shown by histopathologic 
assessment (Fig. 4C). Exogenous rGal1 treatment also mitigated ex-
perimental colitis in WT animals (fig. S7), thus validating its thera-
peutic effect in controlling colitis as previously described in BALB/c 
mice (31). Administration of rGal1 also resulted in down-regulation 
of Ifng and up-regulated expression of Il10 and Il17a in colonic tis-
sue, although it had no impact on the expression of Il5 mRNA 
(Fig. 4D). Moreover, treatment with exogenous rGal1 also reduced 
the percentage of CD69+CD8+ T cells in both MLNs and cLP 
(Fig. 4E), although it had no effect on the proportion of activated 
CD4+ T cells in these compartments (Fig. 4F). Noticeably, the Treg 
percentage in MLNs and cLP of Lgals1−/− mice remained invariant 
in response to the administration of rGal1 (fig. S8). Together, our 
findings indicate that administration of exogenous rGal1 restored 
cytokine production and reversed the increase in CD8+CD69+ T cells 
but had no impact on the augmented frequency of CD4+CD69+ 
T cells observed in Lgals1 −/− mice.
Given the central role of endogenous Gal1 in TNBS-induced 
colitis, we evaluated the possibility that changes in the glycosylation 
signature of CD4+ and CD8+ T cells in the cLP might influence the 
activity of this lectin and its capacity to promote resolution of intes-
tinal inflammation. Although inflammation had no significant im-
pact on the glycophenotype of CD4+ T cells in the cLP (Fig. 5, A to F), 
we identified a significant decrease in (2,6) sialylation in CD8+ 
T cells that correlated with an increase in Gal1 binding to these cells 
(Fig. 5, A and B). Hence, intestinal inflammation in this model pro-
moted a switch in the glycan profile of cLP CD8+ T cells, as evi-
denced by a decrease in (2,6) sialylation and a consequent increase 
in Gal1 binding. To determine whether differential (2,6) sialylation 
induced by intestinal inflammation in CD8+ T cells is restricted to 
inflamed cLP, we compared the glycophenotype of CD8+ and CD4+ 
T cells isolated from spleen and MLNs. TNBS-induced inflamma-
tion had no impact on the glycosylation profiles of these cell popu-
lations, although we did identify several baseline differences based 
on location; for example, T cells from MLNs exhibited lower levels 
of (1,6) N-glycan branching compared to T cells isolated from the 
spleen (fig. S9).
To link decreased (2,6) sialylation of CD8+ T cells induced by 
inflammation with the immunoregulatory activity of Gal1, we ex-
amined apoptosis of CD4+ and CD8+ T cells triggered by this lectin 
in MLNs of WT mice compared to those from St6gal1-deficient 
(St6gal1−/−) mice. Of note, we observed no significant differences 
in cell proliferation when comparing mice of these two genotypes 
(fig. S10). However, our results showed that activated CD4+ and 
CD8+ MLNs T cells from St6gal1−/− hosts (Fig. 5, G and H) were 
more sensitive to Gal1-induced apoptosis, thus emphasizing the 
relevance of (2,6) sialylation in the context of Gal1 function. Notably, 
MLNs CD8+ T cells were more sensitive to Gal1-induced apoptosis 
than MLNs CD4+ T cells (Fig. 5, G and H). The proportions of colonic 
CD8+SNA+ T cells were comparable in WT and Lgals1−/− animals 
during the course of TNBS-induced colitis, although there was a ten-
dency toward decreased apoptotic CD8+SNA− T cells in Lgals1−/− mice, 
as indicated by active Caspase-3 staining (fig. S11). Together, these 
results suggest that CD8+ T cells are major targets of the immuno-
regulatory effect of this lectin within the local gut microenvironment.
Endogenous Gal1 does not influence the development 
of DSS-induced colitis
As no experimental colitis model can fully recapitulate the multifac-
torial nature of human IBD, we also explored the role of endoge-
nous Gal1 in a model of DSS-induced colitis. Notably, no significant 
differences with respect to the development of colitis were identi-
fied when comparing WT and Lgals1−/− mice (fig. S12, A to D). 
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Fig. 4. Treatment with rGal1 partially ameliorates exacerbated colitis in Lgals1−/− mice. (A) Weight loss curves of Lgals1−/− mice treated either with ethanol (vehicle) 
or TNBS that received daily injections with PBS or 100 g of rGal1. Data are from three independent experiments; two-way repeated-measures ANOVA followed by Tukey’s 
posttest. (B) Colon weight/length ratio. Data are from a representative of three independent experiments (n = 5 mice per group). (C) Representative microscopy images 
[hematoxylin and eosin (H&E) staining; 10× magnification] and histopathologic assessment (score) for each experimental group as described in (A). Data are from a 
representative of three independent experiments (n = 5 mice per group). (D) Determination of Il5, Il10, Il17a, and Ifng mRNA in colon tissue by RT-qPCR, normalized 
to Gapdh expression. Box plots represent median (line), first and third quartiles (box limits), and minimum and maximum values (bars) from a representative of three 
independent experiments (n = 8 mice per group); two-tailed unpaired Student’s t test. (E) Percentage of CD69+ cells within the total CD8+ T cell population in MLNs and 
cLP. Data are from a representative of three independent experiments (n = 8 mice per group). In MLNs, Kruskal-Wallis followed by Dunn’s posttest; in cLP, one-way ANOVA 
followed by Tukey’s posttest. (F) Percentage of CD69+ cells within the total CD4+ T cell population in MLNs and cLP. Data are from a representative of three independent 
experiments (n = 8 mice per group). In (B), (C), and (F), one-way ANOVA followed by Tukey’s posttest. Unless otherwise stated, data are presented as means ± SEM. 
*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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Fig. 5. TNBS-induced colitis induces a Gal1-permissive glycophenotype in cLP CD8+ T cells. Representative histograms of biotinylated Gal1 (A), Sambucus nigra 
agglutinin (SNA) (B), Lycopersicon esculentum lectin (LEL) (C), Maackia amurensis lectin II (MAL-II) (D), phytohemagglutinin-L (L-PHA) (E), and peanut agglutinin (PNA) 
(F) binding to CD4+ and CD8+ T cells isolated from cLP of WT mice treated with ethanol (vehicle, blue lines) or TNBS (red lines). Gray-shaded lines represent negative controls 
(cells not incubated with biotinylated lectins). Determination of lectin binding within each T cell population is shown. Data are from a representative of two independent 
experiments (vehicle, n = 4 mice; TNBS, n = 5 mice); two-tailed unpaired Student’s t test. (G and H) Annexin V binding to CD4+ (G) or CD8+ (H) T cells from MLNs isolated from 
WT or St6gal1−/− mice that were activated for 3 days with anti-CD3/anti-CD28 antibodies and incubated for 16 hours with 10 M rGal1 or PBS. Data are from five independent 
experiments; two-way ANOVA followed by Tukey’s posttest. Unless otherwise stated, data are presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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Moreover, we found no alterations in the T cell compartment of the 
MLNs of DSS-treated Lgals1−/− mice when compared to their WT 
counterparts (fig. S12E). Their respective cytokine profiles were the 
only differences observed in DSS-treated Lgals1−/− mice compared 
to WT controls. Specifically, our findings revealed an increase in 
interleukin-17A (IL-17A) protein expression in Lgals1−/− mice (fig. 
S12F). Thus, we conclude that the restorative properties of Gal1 
may rely upon unique mechanisms governing the inflammatory 
processes associated with specific pathological settings.
The glycosyltransferases ST6Gal1 and C2GnT1 control 
the severity of colitis and govern Gal1 
immunoregulatory activity
Most of the characterized anti-inflammatory activities of Gal1 rely 
on its function in the extracellular milieu and the availability of ter-
minal LacNAc structures present in core 2 O-glycans and complex 
branched N-glycans (6). Given the decrease in C2GNT1 mRNA ex-
pression and the increase in ST6GAL1 mRNA in colon biopsies of 
patients with IBD (Fig. 2, C and D), we performed a series of exper-
iments designed to evaluate the aberrant glycosylation (as observed 
in C2gnt1−/− and St6gal1−/− mice) and its influence on the severity 
of experimental colitis. In particular, we focused on a model of colitis 
involving the adoptive transfer of immune cells to immunodeficient 
mice; this strategy facilitates the selective assessment of the impact 
of T cell glycosylation and its role in promoting intestinal inflammation.
In the first experiment, CD4+CD45RBhigh T cells isolated from 
C2gnt1−/− mice were transferred into Rag2−/− mice. Compared to 
mice injected with WT cells, those receiving C2gnt1−/− T cells ex-
hibited earlier onset of disease (~2 to 3 weeks after transfer) and 
more pronounced weight loss, indicative of increased disease sever-
ity (Fig. 6, A and B). Furthermore, mice that received C2gnt1−/− 
CD4+CD45RBhigh T cells exhibited higher levels of Ifng and lower 
levels of Il5 expression in the colon when compared to mice that 
received WT T cells (Fig. 6C). Last, no differences were detected 
between the two experimental groups with respect to the percentage 
of Foxp3+ Tregs (Fig. 6D). As anticipated, CD4+ T cells isolated from 
Rag2−/− mice that were recipients of C2gnt1−/− T cells bound con-
siderably less rGal1 than did those receiving cells from WT mice 
(fig. S13), thus confirming the essential role of core 2 O-glycans for 
Gal1 binding. Thus, the absence of core 2 O-glycans, particularly on 
CD4+ T cells, has a significant impact on the development of intes-
tinal inflammation and results in impaired Gal1 binding.
Because (2,6)-linked sialic acids mask Gal1 binding to their cell sur-
face receptors and thus interfere with Gal1 function, our next set of experi-
ments focused on the in vivo transfer of St6gal1−/− CD4+CD45RBhigh 
T cells into Rag2−/− mice. The results of these experiments showed 
delayed weight loss (detected at ~6 weeks after transfer) compared 
to mice receiving WT CD4+CD45RBhigh T cells (Fig. 6E). Although 
no significant differences in colon weight/length ratio were found 
(Fig. 6F), mice that received St6gal1−/− T cells responded by ex-
pressing less Ifng mRNA and generating higher frequencies of Tregs 
both in MLNs and cLP (Fig. 6, G and H). As anticipated, CD4+ T cells 
from Rag2−/− mice that received St6gal1−/− T cells bound more rGal1 
compared to those receiving WT T cells (fig. S13). Hence, our data 
indicate that (2,6) sialylation, particularly on CD4+ T cells, aug-
ments the severity of intestinal inflammation.
To explore the relevance of glycosylation beyond its role with 
respect to CD4+ T cells, we further evaluated the function of 
C2GnT1 and ST6Gal1 and their influence on the restorative functions 
of Gal1 in the double-dose TNBS-induced colitis model. Mice lack-
ing C2GnT1 exhibited exacerbation of TNBS-induced colitis that 
was associated with increased mortality in comparison to WT mice 
(Fig. 7, A to C). Administration of rGal1 did not suppress intestinal 
inflammation in C2gnt1−/− mice; these mice experienced continu-
ous weight loss, persistent tissue inflammation, and increased 
mortality in response to TNBS-induced colitis (Fig. 7, A to C). 
These results emphasize the critical role of core 2 O-glycans in con-
trolling Gal1 function. By contrast, TNBS-treated St6gal1−/− mice 
experienced a milder form of experimental colitis when compared 
to WT mice (Fig. 7, D to F). Notably, we found no differences in 
the cytokine profiles between vehicle-treated and TNBS-treated 
St6gal1−/− mice (fig. S14). Thus, a glycosylation “on-off” switch, 
regulated by C2GnT1 and ST6Gal1, controls intestinal inflamma-
tion by creating or masking Gal1-specific glycoepitopes.
DISCUSSION
A more complete understanding of the nature and significance of 
tolerogenic programs and the various mechanisms that control 
intestinal homeostasis is critical for the development of rational 
therapeutic strategies aimed at treating patients with IBD. Given 
the broad immunoregulatory activity of Gal1 (9) and its therapeutic 
potential in T cell–mediated autoimmunity (8), we investigated the 
role of endogenous Gal1 and its glycosylated ligands in the develop-
ment, severity, and resolution of gut inflammation. In this study, 
using different experimental mouse models and clinical samples 
from patients with IBD, we identified a glycosylation-dependent 
on-off circuit driven by Gal1 that controls T cell activity in intestinal 
inflammation.
Our analysis of publicly available datasets as well as RT-qPCR 
data from a local cohort of patients with IBD revealed an increase in 
Gal1 expression in intestinal tissue when involved in the inflamma-
tory process; these findings are similar to those previously described 
in association with other intestinal pathologies, including celiac dis-
ease (12, 34). Although it has been recently reported that patients 
with IBD exhibit increased levels of circulating Gal1 (35), we did 
not find significant differences in plasma concentrations between 
patients and control individuals. These discrepancies could be at-
tributed to differences in genetic backgrounds in the cohorts ana-
lyzed or different criteria in patients’ stratification. Moreover, we 
observed increased expression of Gal1 protein in the gastrointesti-
nal tract of mice in the TNBS-induced colitis model. Of note, the 
discrepancies in Gal1 expression in this model compared to that 
previously reported (31) could be attributed to the TNBS adminis-
tration protocol (single dose versus double dose) or strain-dependent 
differences (BALB/c versus C57BL/6 mice). This interpretation is 
consistent with previous studies in which strain-dependent differ-
ences in Gal1 expression in models of DSS-induced colitis were 
reported (36). Lgals1−/− mice presented a more severe form of colitis 
with higher amounts of interferon- (IFN-) in cLP, and treatment 
with exogenous rGal1 partially attenuated this exacerbated inflam-
matory response through up-regulation of IL-10 and down-regulation 
of IFN-. The increase in IL-10 production may be the result of the 
coordinated action of distinct mechanisms responsible for orches-
trating tolerogenic circuits in the gut, including the induction of 
type 1 Tregs via activation of the cellular musculoaponeurotic fibro-
sarcoma (c-Maf)/aryl hydrocarbon receptor pathway (37), differenti-
ation of tolerogenic DCs via phosphorylation of signal transducer 
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Fig. 6. Intrinsic T cell glycosylation influences development of colitis in an adoptive-transfer T cell model. (A) Weight loss curves of Rag2−/− mice following adoptive 
transfer of either WT or C2gnt1−/− CD4+CD45RBhigh T cells. (B) Colon weight/length ratio. (C) Determination of Il5, Il10, Il17a, and Ifng mRNA in colon tissue by RT-qPCR, 
normalized to Gapdh mRNA expression. (D) Percentage of Tregs within total CD4+ T cells in MLNs and cLP. (E) Weight loss curves of Rag2−/− mice after adoptive transfer of 
either WT or St6gal1−/− CD4+CD45RBhigh T cells. (F) Colon weight/length ratio. (G) Determination of Il5, Il0, Il17a, and Ifng mRNA in colon tissue by RT-qPCR, normalized to 
Gapdh mRNA expression. (H) Percentage of Tregs within CD4+ T cells in MLNs and cLP. Experiments described in this figure were performed simultaneously, so values for 
WT mice are identical and only included in separate panels for the sake of clarity. In (A) and (E), two-way repeated-measures ANOVA followed by Dunnett’s posttest. In (C) 
and (G), box plots represent median (line), first and third quartiles (box limits), and minimum and maximum values (bars). In (C), (D), (G), and (H), one-way ANOVA followed 
by Dunnett’s posttest. In all cases, data are from a representative of two independent experiments (n = 5 mice per group). Unless otherwise stated, data are presented as 
means ± SEM. *P < 0.05 and **P < 0.01.
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and activator of transcription 3 (24), reprogramming of M1 in-
flammatory macrophages (38, 39), and/or promotion of anti- 
inflammatory enterocyte programs (40). These results highlight 
the essential role of endogenous Gal1 as an anti-inflammatory me-
diator that promotes resolution of autoimmune inflammation and 
restores immune cell homeostasis, as has been described in models 
of autoimmune neuroinflammation and inflammatory arthritis (8). 
This immunomodulatory lectin is released at times of cellular stress 
and aids to counterbalance exuberant inflammation and tissue 
damage (9). In line with this evidence, we recently found that aged 
Lgals1−/− mice develop spontaneous salivary gland autoimmunity, 
characterized by increased TH1 responses (41). This phenotype is 
not restricted to Gal1 since Lgals3−/− mice develop a lupus-like disease 
with spontaneous germinal center formation (42). The paradoxical 
up-regulation of IL-17A observed in Lgals1−/− mice in response to 
rGal1 treatment may reflect the dual pro- and anti-inflammatory 
role of the IL-17 cytokine family within the gut microenvironment 
(5). Members of the IL-17 cytokine family may drive mucosal in-
flammation, but they might also aid in restitution and repair of the 
intestinal mucosa after resolution (43). Moreover, in the TNBS- 
induced colitis model, TH1-dependent immunity appears to be the 
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Fig. 7. C2GnT1 and ST6Gal1 glycosyltransferases reciprocally control the development of TNBS-induced colitis. (A) Weight loss curves of WT and C2gnt1−/− 
mice treated with ethanol (vehicle), TNBS, or TNBS and rGal1. (B) Kaplan-Meier (survival) curves of WT and C2gnt1−/− mice with TNBS-induced colitis treated or not 
with rGal1. (C) Colon weight/length ratio. (D) Weight loss curves of WT and St6gal1−/− mice treated with ethanol (vehicle) or TNBS. (E) Kaplan-Meier (survival) curves of 
WT and St6gal1−/− mice with TNBS-induced colitis. (F) Colon weight/length ratio. Experiments described in this figure were performed simultaneously, so values for WT 
mice are identical and only included in separate panels for the sake of clarity. In (A) and (D), data are from a representative of two independent experiments (n = 5 mice 
per group); two-way repeated-measures ANOVA followed by Tukey’s post-test. In (B) and (E), data are presented as mean survival proportions from a representative 
of two independent experiments (n = 7 mice per group); Mantel-Cox (log-rank) test. In (C) and (F), data are from a representative of two independent experiments (n = 5 
mice per group); two-way ANOVA followed by Tukey’s posttest. Unless otherwise stated, data are presented as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, and 
****P < 0.0001.
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regulatory roles in mucosal inflammation, as IL-17A production can 
suppress the induction of transcription factor T-box expressed in 
T cells (T-bet), a major regulator of IFN- production (44). In this 
sense, increased amounts of IL-17A induced by Gal1 were accom-
panied by a decrease in IFN- production and an increase in IL-10, 
and these effects may counteract the potential proinflammatory 
effects of IL-17A. In particular, TNBS- induced inflammation was 
associated with elevated levels of IFN-, and prevention of IFN- 
production by anti–IL-12p40 treatment completely abrogated both 
nascent and established disease (45).
Notably, we observed an increase in the percentage of CD69+ 
T lymphocytes in both CD8+ (cLP and MLNs) and CD4+ (MLNs) 
T cell compartments in Lgals1−/− mice. Administration of exoge-
nous rGal1 partially restored the original knockout phenotype by 
targeting the CD8+CD69+ population; by contrast, CD4+CD69+ 
MLNs T cells were refractory to Gal1-mediated immunoregulatory 
activity. These results suggest that CD4+ T cells from MLNs may 
differ in their sensitivity to Gal1 when compared to splenic T lym-
phocytes (23). These findings suggest that mucosal immune cells 
may exhibit distinct glycosylation signatures compared to those of 
peripheral lymphoid tissues. In this sense, context-dependent 
phenotypes and glycophenotypes have been identified previously 
in both DCs and T cells (46, 47); these findings may depend on dif-
ferent environmental cues, including the cytokine milieu and the 
associated microbiota (48).
Dias et al. (22, 49) recently demonstrated the importance of 
Mgat5 glycosyltransferase in intestinal inflammation; combined re-
sults from these studies and our work suggest that synchronized 
remodeling of complex branched N-glycans, core 2 O-glycans, and 
(2,6) sialylation may ultimately dictate T cell sensitivity or resis-
tance to Gal1 in mucosal inflammatory microenvironments. In this 
sense, we found that TNBS-induced intestinal inflammation lowers 
(2,6) sialylation specifically on CD8+ T cells in cLP. Although the 
molecular mechanisms implicated in these effects remain uncertain, 
this phenotype could be associated with changes in ST6Gal1 expression 
and/or with the activity of inflammation-driven neuraminidases.
We identified a specific subpopulation of CD8+CD69+ T cells as 
a key target of the immune inhibitory action of Gal1. These findings 
suggest that Gal1 may control T cell–driven intestinal inflammation 
by limiting colitis-associated inflammatory CD8+ T cell responses 
(Fig. 8A). In this regard, cytotoxic CD8+ T cells, particularly those 
producing IFN- (i.e., Tc1), have been shown to play a central role 
with respect to the development of 2,4-dinitrobenzenesulfonic acid 
(DNBS)-induced experimental colitis (50). However, unlike CD4+ 
T cells, which are widely studied and have been characterized in 
IBD, the relevance of CD8+ T cells and their role in promoting 
human intestinal inflammation remain controversial. Nevertheless, 
recent work supported a more prominent role for CD8+ T cells in 
the development of intestinal inflammation and highlighted both 
the significance and plasticity of these cells in patients with IBD 
(51–54). Lack of immunoregulatory activity of Gal1 in DSS-induced 
colitis may reflect differences in the immunopathogenic mecha-
nisms associated with DSS-induced versus TNBS- induced models, 
potentially involving innate immunity (i.e., neutrophils and macro-
phages) or adaptive T cell responses, respectively (55, 56). These 
results further emphasize the critical role of Gal1 in promoting res-
olution of T cell–mediated inflammation and uphold the relevance 
of further work to validate potential translational applications of 
these findings.
The functional activity of Gal1 is critically influenced by cell 
type–specific expression, subcellular compartmentalization, and 
activity of key glycosyltransferases, which can either mask or un-
mask Gal1-specific glycoepitopes (6). Of note, results from our pa-
tient cohort revealed significant up-regulation of ST6GAL1 mRNA 
in biopsies taken from uninflamed areas of the colon in patients with 
IBD. These results indicated that dysregulation of glycosyltransfer-
ases may not be an exclusive feature of the inflamed tissue. It is not 
clear yet whether alterations in the cellular glycome occur as early 
events or as a result of chronic inflammation. In this regard, it is 
also possible that alterations in the cellular glycome may precede 
and facilitate the inflammatory process. These critical points should 
be further clarified. Moreover, single-cell analysis will help to 



















Fig. 8. Modulation of intestinal inflammation via glycosylation-dependent 
pathways. (A) Intestinal inflammation in TNBS-induced colitis alters the extent of 
(2,6) sialylation in CD8+CD69+ T cells. This altered glycophenotype makes these 
cells more sensitive to the immune inhibitory action of Gal1 and recalibrates T cell 
responses. (B) Role of T cell glycosylation in potentiating or attenuating intestinal 
inflammation in an adoptive transfer model of colitis. Compared to WT T cells, 
C2gnt1−/− T cells increase disease severity, generating an earlier onset and more 
pronounced weight loss. Thus, the absence of core 2 O-glycans on CD4+ T cells in-
fluences the development and severity of intestinal inflammation. On the other hand, 
St6gal1−/− T cells transferred to Rag2−/− mice induce a milder intestinal inflamma-
tion with a delayed onset, higher proportions of Tregs and lower IFN- production.
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Findings from our study reveal that both core 2 O-glycans and 
(2,6) sialylation play essential roles in modulating intestinal in-
flammation as has been described previously for other tissues, in-
cluding the fetal-maternal unit and the liver (57, 58). Our in vivo 
studies featuring the TNBS-induced colitis model revealed decreased 
(2,6) sialylation in colonic CD8+ T cells; these findings indicate 
that aberrant T cell responses may be suppressed through a glycan- 
dependent mechanism (Fig. 8A). In this regard, ST6Gal1-deficient 
MLNs T cells were more sensitive to the immune inhibitory activity 
of Gal1, suggesting that altered (2,6) sialylation could contribute 
to resolution of intestinal inflammation. Accordingly, adoptive 
transfer of St6gal1−/− CD4+CD45RBhigh T cells was associated with 
delayed onset of inflammation and induced higher proportions of 
Tregs and lower IFN- production (Fig.  8B). Although this effect 
may be partially linked to Gal1-mediated down-regulation of T cell 
function, we cannot exclude the possibility that T cells lacking 
ST6Gal1 could be intrinsically hyporeactive upon T cell receptor 
recognition of its cognate antigen (59) or that there may be altered 
responses to other glycan-recognizing proteins including not only 
members of the galectin family but also siglecs via recognition of 
sialic acid ligands (60). Nonetheless, apart from its association with 
immune-associated glycan-binding proteins, sialic acid has emerged 
as a key determinant of immune cell homeostasis in the gut. Alter-
ations in the intestinal sialylation signature may involve different 
mechanisms beyond transcriptional alteration of glycosyltransferase 
expression or induction of epigenetic changes, as pathogenic stim-
uli could trigger expression of endogenous neuraminidases that 
could also influence the sialylation profile (61).
In addition, our results demonstrate that core 2 O-glycans shape 
the course of intestinal inflammation and may critically influence 
the immunomodulatory activity of Gal1. The fact that rGal1 did not 
influence the recovery of C2gnt1−/− mice with TNBS-induced colitis 
indicates that this glycosyltransferase likely plays an essential role in 
the immunomodulatory and therapeutic activity of this lectin. 
Moreover, C2gnt1−/− mice developed an aggravated form of colitis; 
adoptive transfer of C2gnt1−/− CD4+CD45RBhigh T cells into Rag2−/− 
mice resulted in an exacerbation of colitis (Fig. 8B), characterized 
by increased IFN- production. These results highlight the signifi-
cance of C2GnT1 expressed by mucosal CD4+ T cells in modulating 
their fate and function in the intestinal microenvironment. Accordingly, 
previous studies revealed that C2gnt1−/− mice were more susceptible 
to DSS treatment (18) and demonstrated involvement of this glyco-
syltransferase in regulating memory CD4+ T cell proliferation (21).
In summary, our study highlights the relevance of cLP T cell 
glycosylation in potentiating or tempering intestinal inflammation 
via mechanisms that result in either masking or unmasking Gal1- 
specific glycoepitopes. Together, these findings suggest a critical 
role for the Gal1-glycan axis in preserving immune homeostasis in 
the gut. Although we focused our attention on core 2 O-glycans and 
terminal (2,6) sialylation as critical determinants of Gal1 intestinal 
function, Dias and colleagues (22,  49) demonstrated that (1,6)-
branched N-glycan structures and Mgat5 also played critical roles 
with respect to the pathogenesis of UC. This effect, which correlated 
with disease severity, could be reversed by metabolic supplementa-
tion with N-acetylglucosamine (22, 49). Future studies should be 
aimed at elucidating whether both complex N-glycans and core 2 
O-glycans jointly assist Gal1-driven tolerogenic circuits to preserve 
and/or restore gut homeostasis. Collectively, our results emphasize 
the critical role of endogenous Gal1 as an immune checkpoint 
pathway that controls intestinal inflammation via glycosylation- 
dependent contraction of the CD8+ T cell compartment and modu-
lation of inflammatory cytokines.
MATERIALS AND METHODS
Bioinformatic analysis
We chose three curated microarray experiments from the GEO 
Dataset Browser (www.ncbi.nlm.nih.gov/sites/GDSbrowser/) with 
colonic biopsies from healthy donors (controls) and patients with 
IBD: GSE6731 (U.S. cohort; controls, patients with UC, and patients 
with CD), GSE9452 (Denmark cohort; controls and patients with 
UC), and GSE38713 (Spain cohort; controls and patients with UC). 
Criteria were based on three restrictions: (i) All genes of interest 
should be contained in the microarray, (ii) genes should have vali-
dation by RT-qPCR, and (iii) datasets should contain samples from 
inflamed and uninflamed areas of the colon from patients with 
IBD. Galectins mRNA (LGALS1, LGALS2, LGALS3, LGALS4, 
LGALS7, LGALS8, and LGALS9) and transcripts for selected glyco-
syltransferases (ST6GAL1, MGAT5, and C2GNT1) were analyzed 
through the online platform GEO2R (www.ncbi.nlm.nih.gov/geo/
geo2r/), and data were represented as the logarithm in base 2 of the 
fold change (FC) with respect to controls.
Patients
This study was approved by the Ethics Committees of Instituto de 
Biología y Medicina Experimental (IBYME-CONICET) and Hospital 
de Gastroenterología “Dr. Carlos Bonorino Udaondo” (Buenos 
Aires, Argentina). In all cases, tissue samples were obtained with 
the written informed consent of patients. EDTA-anticoagulated 
blood samples and/or colon biopsies were collected from 23 pa-
tients with UC, 12 patients with CD, and 11 healthy controls, who 
had undergone endoscopic examinations for routine health mainte-
nance to diagnose intestinal conditions that were not linked to 
inflammatory diseases, including abdominal pain, constipation, or 
screen for colorectal cancer. Clinical data are presented in Table 1. 
IBD was ruled out in all the healthy controls by clinical, endoscopic, 
and conventional histologic criteria. Patients with IBD were diag-
nosed on the basis of clinical, endoscopic, and histopathologic find-
ings according to currently accepted criteria (62). Clinical disease 
activity was assessed by two expert gastroenterologists using the 
Crohn’s Disease Activity Index for patients with CD and the partial 
Mayo Score for patients with UC (63, 64). CD- or UC-associated 
disease activity observed on endoscopy was evaluated according to 
the Inflammatory Bowel Disease in South-Eastern Norway (IBSEN) 
(65), which is an index that includes a scale of endoscopic activity 
considered by the European Evidence-Based Consensus for Endoscopy 
in IBD (66). In contrast to the Mayo sub-endoscopic scoring, 
Crohn’s Disease Endoscopic Index of Severity, and Simple Endoscopic 
Score for Crohn’s Disease, the IBSEN score has been designed for 
use in evaluation of both UC and CD. Hence, this scale allowed us 
to perform parallel evaluations in patients with different diagnoses 
but with comparable disease severity. Inflammation severity of 
human intestinal mucosa was classified by endoscopic criteria, and 
sample classification was binarized into either inflamed or uninflamed 
categories on the basis of assessment by an endoscopist. Scores were 
based on findings from colonic segments from sites of biopsy tissue. 
Briefly, the inflammatory status of the mucosae was scored from 
0 to 2 by endoscopic evaluation by a single observer who is a 
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gastroenterologist with expertise in endoscopic evaluation of IBD. Seg-
ments received scores of 0 (normal/no signs of inflammation), 
1 (light erythema or granularity), or 2 (granularity, friability, and 
bleeding, with or without ulcerations). We designated scores of 
1 and 2 in the inflamed areas as weak and marked inflammation, 
respectively. Total colonoscopy was performed in all patients with 
IBD and healthy controls. Four adjacent biopsy samples were re-
covered from IBD patients with endoscopically active disease, de-
fined as “inflamed” and focusing in each patient on those regions with 
the highest score (most severe disease activity, including granularity, 
and/or friability, bleeding, with or without ulcerations). Meanwhile, 
samples defined as “uninflamed” were obtained from each patient 
from (i) areas with endoscopically quiescent (inactive) disease with 
endoscopic score 0 (defined as “normal” in IBSEN score at the time 
of study, although some of them had been previously identified as 
active) and (ii) areas with similar appearance but with neither cur-
rent macroscopic inflammation nor any history of previous disease 
activity. Biopsies of the same segment from each patient were pooled, 
and inflamed or uninflamed areas were compared to each other, as 
well as to samples from healthy controls. This allowed us to per-
form direct comparisons between tissue segments from fully healthy 
controls with those from patients with IBD based on disease activity 
(inflamed or uninflamed as defined at the time of the colonoscopy).
RNA extraction and RT-qPCR
Total RNA was purified from human colon biopsies and mouse 
colon samples using TRIzol reagent (Life Technologies, Thermo 
Fisher Scientific) and deoxyribonuclease I (DNAse I; Amplification 
Grade, Thermo Fisher Scientific). Copy DNA was synthesized using 
SuperScript II Reverse Transcriptase (Thermo Fisher Scientific), ac-
cording to the manufacturer’s instructions in the presence of ran-
dom hexamers (2.5 g/ml), deoxynucleotide triphosphates (500 nM), 
and 20 U of RNAseOUT (Thermo Fisher Scientific). Gene expres-
sion was analyzed using SYBR Green PCR Master Mix (Applied 
Biosystems, Thermo Fisher Scientific) and CFX96 Touch Real-Time 
PCR Detection System (Bio-Rad). All reactions were performed in 
duplicate in the presence of suitable primers, purchased from Inte-
grated DNA Technologies, with glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) as loading control (300 nM of each primer). Primer 
sequences used were human LGALS1 forward: 5′-CCTGGAGAGTG-
CCTTCGAGTG-3′, reverse: 5′-CTGCAACACTTCCAGGCTGG-3′; 
human LGALS3 forward: 5′-CCAACGAGCGGAAAATGG-3′, reverse: 
5′-CATCCTTGAGGGTTTGGGTTT-3′; human LGALS4 forward: 
5′-CTGGTCTTCATAGTCCTGGCTGAG-3′, reverse: 5′-AGGCT-
GTTCCGGACCACG-3′; human LGALS9 forward: 5′-CGTGTGG-
ACACCATCTCCG-3′, reverse: 5′-CAGCCCTCCCAGAATGGTG-3′; 
human ST6GAL1 forward: 5′-ATCGTAAGCTGCACCCCAAT-3′, 
reverse: 5′-ATGATACCAAGCATCCCAGAGG-3′; human MGAT5 
forward: 5′-TGCCCCTGCCGGGACTTCAT-3′, reverse: 5′-CAGCAG-
CATGGTGCAGGGCT-3′; human C2GNT1 forward: 5′-CTACCCG-
CCCTGCGATG-3′, reverse: 5′-CATCCAGTTCAAGTCACCAGCTC-3′; 
human GAPDH forward: 5′-GATGCCCCCATGTTTGTGAT-3′, 
reverse: 5′-GGTCATGAGTCCTTCCACGAT-3′; mouse Ifng 
forward: 5′-GGCTGTTACTGCCACGGCACA-3′, reverse: 
5′-CACCATCCTTTTGCCAGTTCCTCCA-3′; mouse Il5 forward: 
5′-ACACA GCTGTCCGCTCACCG-3′, reverse: 5′-TCCACAGTACCCC-
CACGGACA-3′; mouse Il10 forward: 5′-TTCCCTGGGTGAGA-
AGCTGA-3′, reverse: 5′-CTTCACCTGCTCCACTGCCT-3′; 
mouse Il17a forward: 5′-CTCCAGAAGGCCCTCAGACTAC-3′, 
reverse: 5′-AGCTTTCCCTCCGCATTGACACAG-3′; mouse Tnf 
forward: 5′-TACTGAACTTCGGGGTGATCG-3′, reverse: 5′-TGAT-
GAGAGGGAGGCCATTT-3′; and mouse Gapdh  forward: 
5′-CAGAACATCA TCCCTGCAT-3′, reverse: 5′-GTTCAGCTCT-
GGGATGACCTT-3′.
Plasma Gal1 determination
Plasma from patients with IBD and healthy controls were obtained 
from EDTA-anticoagulated blood samples by centrifugation (500g, 
10 min). Circulating Gal1 levels were measured by an in-house en-
zyme-linked immunosorbent assay (ELISA) as described (27).
Production of rGal1 and biotinylated Gal1
rGal1 was produced and purified as outlined previously (67). 
Biotinylated Gal1 was obtained using the EZ-Link NHS-LC-Biotin 
kit (Thermo Fisher Scientific) according to the manufacturer’s 
instructions.
Mouse strains
Mice used in this study (all on a C57BL/6 background) were main-
tained in the animal facilities of IBYME-CONICET under a 12-hour 
light/12-hour dark regime. C57BL/6 WT, C2gnt1−/−, and Rag2−/− mice 
were purchased from the Jackson laboratory. Lgals1−/− mice were 
originally provided by F. Poirier (Jacques Monod Institute, Paris, 
France), and St6gal1−/− mice were provided by J. Paulson (La Jolla, 
CA, USA). The Institutional Committee for the Care and Use of 
Laboratory Animals of IBYME-CONICET approved all protocols.
TNBS-induced colitis
On the basis of previous protocols for single-dose models (31), we 
generated a double-dose colitis model in 9-week-old male C57BL/6 
mice. Briefly, mice were fasted 8 hours before intrarectal instillation of 
100 l of TNBS solution in ethanol 50% (v/v) (Sigma-Aldrich) or etha-
nol 50% (v/v) alone (vehicle) using an intravenous 20G Teflon catheter 
(Dexal). The TNBS dose was optimized for the C57BL/6-resistant 
strain and calculated for each animal as 0.25 mg/g of body weight. 
Body weight for each animal was monitored daily and normalized 
to the body weight recorded the day before fasting (day −1). At 
day 7 after instillation, animals were reinstilled with intrarectal 
TNBS or vehicle solution using doses adjusted to their body 
weight as described above. At day 10 (3 days after the second in-
stillation), mice were euthanized by cervical dislocation for subse-
quent analysis.
DSS-induced colitis
Chronic colitis was induced in 8- to 10-week-old female C57BL/6 
mice by repeated administration of DSS in drinking water (3 cycles). 
Each cycle consisted of 5 days of administration of sterile-filtered 
tap water with 2.5% (w/v) DSS (molecular weight, 36,000 to 50,000; 
MP Biomedicals Inc.) followed by 5 days of autoclaved tap water. 
Body weights (normalized to weights on day 0), stool consistency, 
and the presence of blood in stool samples were examined three 
times per week. On day 30, animals were euthanized by cervical dis-
location for subsequent analysis.
Adoptive transfer of CD4+CD45RBhigh T cells to Rag2−/− mice
CD4+ T cells were isolated from spleens of 10- to 12-week-old male 
WT, St6gal1−/−, or C2gnt1−/− mice using the Dynabeads Untouched 
Mouse CD4 Cells kit (Thermo Fisher Scientific) according to the 
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manufacturer’s instructions. Enriched CD4+ T cells (>80% purity) 
were labeled with Alexa Fluor 647–conjugated anti-mouse CD4 
(RM4-5, BD Pharmingen) and fluorescein isothiocyanate (FITC)–
conjugated anti-mouse CD45RB (16A, BD Pharmingen) antibodies 
for 30 min at 4°C. CD4+CD45RBhigh T cells were isolated using a 
FACSAria II cell sorter (Becton Dickinson) to >90% purity; these 
cells were washed, counted, and resuspended in sterile phosphate- 
buffered saline (PBS). Rag2−/− mice (10 to 12 weeks old) were injected 
intraperitoneally with 500,000 CD4+CD45RBhigh T cells (WT, St6gal1−/−, 
or C2gnt1−/−) for induction of colitis. Body weights for each mouse 
were taken weekly and normalized individually to body weights be-
fore T cell transfer (week 0). At week 10 after T cell transfer, animals 
were euthanized by cervical dislocation for subsequent analysis.
Administration of rGal1 in TNBS-induced colitis
Experimental colitis was induced in male C57BL/6 Lgals1−/− and 
WT mice (8 to 10 weeks old) as described above. TNBS-treated ani-
mals were injected intraperitoneally with 100 g of rGal1 in 100 l of 
PBS daily (from days 0 to 9) or with 100 l of PBS (vehicle) daily. 
Control animals received ethanol 50% (v/v) (vehicle) and were injected 
intraperitoneally with 100 l of PBS daily. Body weight for each animal 
was recorded daily and normalized to the body weight recorded the 
day before fasting (day −1). At day 10, animals were euthanized.
Histological assessment of TNBS-induced colitis
After euthanasia, colon was removed and three tissue samples from 
the proximal, middle, and distal parts of the colon were obtained and 
fixed with 4% formaldehyde in PBS. Paraffin-embedded sections were 
stained with hematoxylin and eosin (H&E). Sections were analyzed 
by a blinded pathologist (M.M.). The severity of colon damage was 
assessed by means of a previously described scoring system (68–70) 
with some modifications, described below. Mucosal integrity is as fol-
lows: 0, normal; 1, isolated cell death (apoptosis); 2, erosions; 3, ulcer-
ation. Score for polymorphonuclear leukocytes (PMN) in lamina propria 
is as follows: 0, 1 to 5 PMN; 1, 6 to 10 PMN; 2, >11 PMN. Cryptitis is 
as follows: 0, absent; 1, with abscesses. Edema is as follows: 0, normal; 1, 
presence of edema. Colon architecture is as follows: 0, normal; 1, 
isolated glandular branches; 2, altered. Lymphocytes in lamina pro-
pria are as follows: 0, 0 to 20; 1, 21 to 40; 2, 41 to 60; 3, >61.
Histological assessment of DSS-induced colitis
After euthanasia, colons were removed and tissue samples from the 
distal part of the colon were extracted for histologic analysis. Tissue 
samples were fixed in 4% formaldehyde in PBS. Paraffin-embedded 
sections were stained with H&E. A blind examination on histologi-
cal sections was performed by a pathologist (M.M.). The severity of 
colonic damage was assessed by means of the scoring system de-
scribed below, adapted from literature (71). Mucosal inflammation 
is as follows: 0, normal; 1, low; 2, moderate; 3, severe. Inflammation 
extension is as follows: 0, normal; 1, mucosa; 2, mucosa and submu-
cosa; 3, transmembrane. Regeneration is as follows: 0, complete 
regeneration; 1, almost complete regeneration; 2, regeneration with 
crypt depletion; 3, non-intact epithelium surface; 4, no separation. 
Crypt damage is as follows: 0, no damage; 1, 1/3 basal; 2, 2/3 basal; 
3, only surface epithelium; 4, entire crypt loss.
Gal1 immunohistochemistry
After euthanasia, colons were removed and tissue samples from the 
distal part of the colon were obtained and fixed with 4% formaldehyde 
in PBS and embedded in paraffin. Sections of 5 µm were dewaxed and 
rehydrated in serial ethanol dilutions. Endogenous peroxidase activity 
was blocked with 3% (v/v) H2O2 for 15 min followed by antigen retrieval 
performed with sodium citrate treatment (10 mM, pH 6.0). Slides 
were stained with rabbit anti-Gal1 polyclonal IgG obtained as previously 
described (27) at 4°C overnight. Gal1 staining was detected using 
the Vectastain Elite ABC kit (Vector Laboratories) according to the 
manufacturer’s instructions or by using anti-rabbit–Alexa Fluor 546 
secondary antibody followed by nuclei staining with 4′,6-diamidino- 2-
phenylindole and processed by confocal microscopy. Micrographs 
were taken with an Olympus CX31 microscope for bright field or in 
an Olympus FV1000 confocal microscope for immunofluorescence.
Preparation of mouse colonic extracts
Tissue samples from the proximal, middle, and distal parts of the 
colon were obtained and mechanically processed in protein ex-
traction buffer [50 mM tris-HCl (pH 7.5), 150 mM NaCl, 10 mM 
EDTA, and 1% NP-40] containing a protease inhibitor cocktail 
(Sigma-Aldrich). Cellular debris was eliminated by centrifugation 
(12,000g, 10 min). Protein concentration was determined in super-
natants using the Micro BCA kit (Pierce) following the manufacturer’s 
instructions.
Determination of Gal1 and cytokines in colonic 
extracts by ELISA
Mouse Gal1 was determined in colonic protein extracts by ELISA 
using specific capture (AF1245, R&D Systems) and detection 
(BAF1245, R&D Systems) antibodies and mouse rGal1 (1245-GA, 
R&D Systems) for the standard curve. Gal1 protein concentration 
was normalized to the amount of total protein measured by the Micro 
BCA kit (Pierce). Murine IL-5, IL-6, transforming growth factor– 1, 
IFN-, IL-17A, and IL-10 were analyzed in colonic protein extracts 
from DSS-treated mice using ELISA kits (R&D Systems), according to 
the manufacturer’s instructions, and relativized to total protein.
Western blot
Total colonic protein extracts (30 g of total protein) were suspended 
in 2× Laemmli sample buffer (Bio-Rad) under reducing conditions 
and subjected to SDS–polyacrylamide gel electrophoresis followed 
by transfer onto Amersham Protran nitrocellulose membranes (GE 
Healthcare). After blocking, membranes were incubated with rabbit 
anti-actin antibody (I-19, Santa Cruz Biotechnology Inc.) and rab-
bit anti-Gal1 polyclonal IgG obtained as previously described (27). 
Membranes were then incubated with horseradish peroxidase– 
labeled anti-rabbit secondary antibody (Bio-Rad) and developed 
using ECL Prime Western Blotting Detection Reagent (Amersham 
Biosciences). Protein bands were analyzed with ImageJ software.
Isolation of leukocytes from the spleen, MLNs, and cLP
Spleens and MLNs were removed and mechanically disrupted in com-
plete RPMI 1640 media (Gibco), supplemented with 10% fetal bovine 
serum (FBS; Gibco). Afterward, cells were passed through a 70-m 
Falcon cell strainer (Thermo Fisher Scientific) and washed twice with 
PBS. Cells from MLNs were resuspended in PBS containing 10% FBS 
and kept on ice until use. On the other hand, cells from spleens were 
resuspended in 1 ml of ammonium-chloride- potassium (ACK) lysing 
buffer for 5 min to eliminate red blood cells. Afterward, cells were diluted 
in PBS (9 ml) and centrifuged (300g, 10 min). Last, splenocytes were 
resuspended in PBS containing 10% FBS and kept on ice until use.
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Colons were removed and their length and weight were measured 
before processing. Isolation of cLP mononuclear cells was performed 
as follows: Colon specimens were opened longitudinally and washed 
with ice-cold Hank’s balanced salt solution (HBSS) without Ca2+/
Mg2+ (Thermo Fisher Scientific), cut into 3-mm pieces, and incubated 
(37°C, 20 min) with HBSS/EDTA (5 mM) 5% FBS under continuous stir-
ring. To eliminate remnant epithelial cells and EDTA, colon fragments 
were then washed with HBSS (37°C, 20 min). Then, colon fragments 
were placed in C tubes (MACS) and disaggregated (37°C, 50 min) with 
freshly prepared enzymatic solution: collagenase D (1 mg/ml) (Roche), 
dispase II (1 mg/ml) (Sigma- Aldrich), DNAse I (20 U/ml) (Thermo 
Fisher Scientific), and 10% FBS in PBS under continuous stirring. 
After incubation with the enzymatic solution, C tubes were placed in the 
gentleMACS Dissociator (MACS). Disaggregated colonic tissues were 
diluted in ice-cold PBS and filtered through a 100-m Falcon cell 
strainer (Thermo Fisher Scientific). Cells were then resuspended in 
4 ml of 40% Percoll (Percoll, GE Healthcare) in complete Dulbecco’s 
modified Eagle medium (Gibco), which was then layered on top of 
4 ml of 70% Percoll. After centrifugation (680g, 20 min, without brake), 
cells from the interface were collected and washed with PBS. Last, 
cells were resuspended in 10% FBS in PBS and kept on ice until use.
In vitro T cell stimulation and cell death assay
Freshly isolated total lymphocytes (1 × 105) from MLNs of WT and 
St6gal1−/− animals were cultured for 3 days in 100 l of complete RPMI 
1640 media supplemented with 10% FBS and agonistic anti- mouse 
CD28 antibody (1 g/ml) (37.51, Bio X Cell) in a CellStar U-bottom 
96-well culture plate (Greiner Bio-One) previously coated with 100 l 
of agonistic anti-mouse CD3 antibody (5 g/ml) (145-2C11, Bio X Cell) 
in PBS. After 3 days of polyclonal stimulation, cells were harvested 
and washed with PBS. Then, cells were incubated for 16 hours with 
10 M rGal1 or PBS (vehicle), harvested, and stained to determine the 
proportion of apoptotic CD4+ and CD8+ T cells by flow cytometry.
Flow cytometry
Flow cytometry was performed using a FACSCanto II cytometer 
(Becton Dickinson), and data were analyzed with FlowJo software 
(V.10.0.7r2; FlowJo LLC). Leukocytes from spleen, MLNs, or cLP 
were prepared for flow cytometry analysis as follows: Tregs were la-
beled with anti-mouse CD4-FITC (RM4-5, BD Pharmingen) and 
anti- mouse CD25-phycoerythrin (PE) (PC61, BD Pharmingen) anti-
bodies in cytometry buffer (PBS, 1% FBS, and 0.02% NaN3) for 
30 min at 4°C. Cells were then fixed and permeabilized with the 
Intracellular Fixation & Permeabilization Buffer set (eBioscience) 
according to the manufacturer’s instructions. Foxp3 was labeled 
with anti-mouse Foxp3–Alexa Fluor 647 (MF23, BD Pharmingen) 
in permeabilization buffer (eBioscience) for 30 min at 4°C. Last, 
cells were washed with permeabilization buffer and resuspended 
in cytometry buffer until analysis. Activated T cells were labeled 
with anti-mouse CD4-PE (RM4-4, BioLegend), anti-mouse CD8-
PE-Cy7 (53-6.7, BioLegend), and anti-mouse CD69-FITC (H1.2F3, 
BD Pharmingen) antibodies in cytometry buffer for 30 min at 
4°C. Cells were then fixed with 1% formaldehyde. Colonic resi-
dent memory T cells were labeled using the previously described 
antibodies and anti-mouse CD103-allophycocyanin (APC) (2E7, 
eBioscience) following the same protocol.
For lectin binding assays, spleen, MLNs, or cLP cells were incu-
bated for 30 min with 10 M biotinylated lectins in buffer A 
[150 mM NaCl, 10 mM Hepes (pH 7.4), and 1% bovine serum albumin]. 
Afterward, cells were washed with buffer A and incubated with 
streptavidin-PE (BD), anti-mouse CD4-APC (RM4-5, BD Pharmingen) 
and anti-mouse CD8-FITC (53-6.7, BioLegend) antibodies for 30 min 
at 4°C. The excess of antibodies and streptavidin was washed with 
buffer A. Last, cells were fixed with 1% formaldehyde in PBS. Lectins 
used in this study include rGal1 and the following plant lectins (all 
from Vector Laboratories): Phytohemagglutinin-L [L-PHA; recognizing 
(1,6)-branched complex N-glycans], Sambucus nigra agglutinin [SNA; 
with specificity for (2,6)-linked sialic acid], Maackia amurensis lectin II 
[MAL-II; which recognizes (2,3)-linked sialic acid], peanut agglutinin 
(PNA; with specificity for asialo-core 1 O-glycans), and Lycopersicon 
esculentum lectin (LEL; recognizing poly-LacNAc residues). Apop-
totic cLP CD8+SNA− T cells were first incubated for 30 min with 
biotinylated SNA in buffer A, as previously described, and subse-
quently labeled with anti-mouse CD8-APC (53-6.7, BioLegend) anti-
bodies in cytometry buffer for 30 min at 4°C. Cells were then stained 
for active Caspase-3 using the Active Caspase-3 Apoptosis Kit (BD 
Pharmingen) according to the manufacturer’s instructions.
Proliferation of in vitro–activated CD4+ and CD8+ T cells from MLNs 
was assessed with anti-mouse CD4-APC (RM4-5, BD Pharmingen) 
and anti-mouse CD8-PE-Cy7 (53-6.7, BioLegend) antibodies using 
Tag-it Violet Proliferation Cell Tracking Dye (BioLegend), accord-
ing to the manufacturer’s instructions. To analyze the percentage 
of annexin V+ T cells, cells were first labeled with anti-mouse 
CD4-APC-Cy7 (RM4-5, BioLegend) and anti-mouse CD8-APC 
(53-6.7, BioLegend) antibodies in cytometry buffer for 30 min at 
4°C. Cells were then stained with annexin V–FITC (BD Pharmingen), 
using annexin V buffer (BD Pharmingen), according to the manu-
facturer’s instructions.
Statistical analysis
GraphPad Prism version 8 (GraphPad Software Inc.) was used for 
statistical analysis. Gene expression meta-analysis of galectins and 
glycosyltransferases in IBD datasets was performed as follows: For 
each gene, data were separated according to biopsies origin (“IBD” 
factor: healthy controls, uninflamed, and inflamed areas of patients 
with IBD) and datasets origin (“Dataset” factor); afterward, the 
main IBD effect was analyzed with two-way analysis of variance 
(ANOVA), followed by Tukey’s posttest. Wasting disease curves 
were compared with two-way repeated-measures ANOVA, followed 
by Tukey’s or Dunnett’s posttest. Two groups were compared with 
two-tailed Student’s t test for unpaired data. For multiple compari-
sons, multiple t test (using the Holm-Sidak correction method), 
one-way or two-way ANOVA followed by Tukey’s or Dunnett’s 
posttests (parametric analysis), or Kruskal-Wallis followed by Dunn’s 
posttest (nonparametric analysis) were used. Kaplan-Meier (survival) 
curves were compared with the Mantel-Cox (log-rank) test. Last, a lin-
ear regression model and Pearson’s coefficient (r) were used for cor-
relation analysis. P values of 0.05 or less were considered significant.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/25/eabf8630/DC1
View/request a protocol for this paper from Bio-protocol.
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